Kiniksa Pharmaceuticals International PLC Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $52.30
- Day Range
- $52.50–54.05
- 52-Week Range
- $26.28–59.84
- Bid/Ask
- $53.86 / $53.99
- Shares Outstanding
- 76.94M
- Market Cap
- $4.14B
- Volume/Avg
- 105,762 / 660,135
Key Statistics
- Price/Earnings (Normalized)
- 52.50
- Price/Sales
- 5.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.19%
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 366
- Website
- https://www.kiniksa.com
Valuation
|
Metric
|
KNSA
|
|---|---|
Price/Earnings (Normalized) | 52.50 |
Price/Book Value | 6.57 |
Price/Sales | 5.54 |
Price/Cash Flow | 31.58 |
Price/Earnings
KNSA
Financial Strength
|
Metric
|
KNSA
|
|---|---|
Quick Ratio | 3.14 |
Current Ratio | 3.79 |
Interest Coverage | — |
Quick Ratio
KNSA
Profitability
|
Metric
|
KNSA
|
|---|---|
Return on Assets (Normalized) | 14.04% |
Return on Equity (Normalized) | 18.79% |
Return on Invested Capital (Normalized) | 18.46% |
Return on Assets
KNSA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Rhpsclrk | Nvysgy | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Mklyfttjv | Tvdhsdd | $40B | |||
| Haleon PLC ADR
HLN
| Hlydrpsl | Rxbmx | $40B | |||
| Zoetis Inc Class A
ZTS
| Tptqrfwzgs | Ktjr | $33B | |||
| Viatris Inc
VTRS
| Fwsvdlm | Zbvnk | $19B | |||
| Elanco Animal Health Inc
ELAN
| Zgbt | Nlpbz | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Bsgsvkqgw | Lyg | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Gndtpth | Kpjj | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Ztbsrcll | Xfwjbb | $2B | |||
| Perrigo Co PLC
PRGO
| Hxrlgyyw | Qql | $2B |
United States